Impact Of Rising Chronic Kidney Disease Cases On The Growth Of The Market Is Supporting Development Across The Roxadustat Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Trend Is Expected For The Roxadustat Market From 2026 To 2030?

The roxadustat market has witnessed significant expansion in recent years. It is projected to climb from $6.86 billion in 2025 to $7.33 billion in 2026, exhibiting a compound annual growth rate of 6.9%. This historical growth can be ascribed to several factors including the extensive presence of chronic kidney disease, the reliance on erythropoiesis-stimulating agents, hospital-centric anemia management, the restricted availability of oral anemia treatments, and the increasing number of dialysis centers.

The roxadustat market is anticipated to experience substantial expansion in the coming years. It is projected to reach $9.56 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.9%. This growth during the forecast period can be attributed to an escalating global burden of anemia, a growing preference for oral treatments, the expanding chronic kidney disease (CKD) patient demographic, an increase in outpatient anemia care, and enhanced availability of novel anemia medications. Key trends anticipated for this timeframe encompass the increasing uptake of oral anemia therapies, the expanding utilization of HIF-PHI drugs, a heightened emphasis on anemia linked to CKD, a transition from injectable ESAs, and broadening access to anemia treatments.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp

What Important Drivers Are Powering The Roxadustat Market Growth?

The increasing incidence of chronic kidney disease (CKD) among individuals is anticipated to boost the expansion of the Roxadustat market in the future. CKD is a persistent medical state characterized by the progressive deterioration of kidney function, frequently culminating in kidney failure without appropriate medical intervention. Globally, the prevalence of chronic kidney disease is escalating, attributed to factors including demographic aging, heightened occurrences of diabetes and high blood pressure, and detrimental lifestyle choices. Roxadustat aids in the management of chronic kidney disease through its action of stimulating erythropoietin production. This process enhances red blood cell generation, thereby alleviating anemia frequently linked with the condition, ultimately leading to better kidney function and an improved quality of life for patients. As an illustration, data from June 2023, provided by Kidney Research UK, a UK-based charitable organization, projects that by 2033, the population experiencing CKD stages 3–5 will likely increase to 3.9 million. Consequently, the growing population afflicted with chronic kidney disease (CKD) is stimulating the development of the Roxadustat market.

What Key Segment Areas Are Included In The Roxadustat Market Assessment?

The roxadustat market covered in this report is segmented –

1) By Type: 20mg, 50mg

2) By Product Formulation: Oral Tablets

3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers

4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions

Which Trends Are Affecting The Roxadustat Market Framework?

Major companies operating in the roxadustat market are directing their efforts towards generating real-world evidence, including observational registry studies, to strengthen the long-term benefit, safety, and utilization patterns of their HIF PH inhibitor therapy. Real-world evidence refers to clinical data gathered outside of controlled trials, within routine practice settings, to accurately represent actual patient experiences. The roxadustat market actively supports this approach by sponsoring large-scale real-world studies, which healthcare payers and regulators are increasingly relying on for assessment. As an illustration, in May 2024, Astellas Pharma, a UK-based company, finalized the launch of the WINE study via the WiNe Registry in Germany, a non-interventional cohort study designed to capture clinical outcomes, dosing characteristics, and hemoglobin response in patients receiving EVRENZO (roxadustat). The findings from this registry help demonstrate roxadustat’s effectiveness within real-world CKD populations and support long-term reimbursement choices. Therefore, the production of real-world evidence is a significant factor driving the expansion of the roxadustat market.

Which Firms Are Competing In The Roxadustat Market?

Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.

Access The Complete Roxadustat Market Report:

https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report

Which Area Represents The Largest Portion Of The Roxadustat Market?

North America was the largest region in the Roxadustat market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Roxadustat Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp

Browse Through More Reports Similar to the Global Roxadustat Market 2026, By The Business Research Company

Rotavators Market Report 2026

https://www.thebusinessresearchcompany.com/report/rotavators-global-market-report

Vermiculite Market Report 2026

https://www.thebusinessresearchcompany.com/report/vermiculite-global-market-report

Agritech Market Report 2026

https://www.thebusinessresearchcompany.com/report/agritech-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795